Discounted Cash Flow (DCF) Analysis Levered
Onconova Therapeutics Inc. Warrants (ONTXW)
$0.0671
-0.02 (-25.44%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 5.55 | 0.79 | 1.23 | 2.18 | 0.23 | 0.21 | 0.19 | 0.17 | 0.15 | 0.13 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -15.81 | -23.82 | -22.70 | -20.83 | -23.07 | -6.67 | -5.98 | -5.36 | -4.80 | -4.31 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | - | -0.06 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -15.81 | -23.82 | -22.70 | -20.89 | -23.09 | -6.68 | -5.99 | -5.37 | -4.81 | -4.31 |
Weighted Average Cost Of Capital
| Share price | $ 0.0,671 |
|---|---|
| Beta | 4.068 |
| Diluted Shares Outstanding | - |
| Cost of Debt | |
| Tax Rate | -0.02 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 22.893 |
| Total Debt | - |
| Total Equity | - |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 5.55 | 0.79 | 1.23 | 2.18 | 0.23 | 0.21 | 0.19 | 0.17 | 0.15 | 0.13 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.81 | -23.82 | -22.70 | -20.83 | -23.07 | -6.67 | -5.98 | -5.36 | -4.80 | -4.31 |
| Capital Expenditure | - | - | - | -0.06 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Free Cash Flow | -15.81 | -23.82 | -22.70 | -20.89 | -23.09 | -6.68 | -5.99 | -5.37 | -4.81 | -4.31 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -4.40 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -19.02 |
| Equity Value | - |
| Shares Outstanding | - |
| Equity Value Per Share | - |